Q4 2025 earnings call highlights: 2026 guidance, KEYTRUDA LOE risks, $70B pipeline outlook, and new launches—read now.
Global therapeutic portfolio spans human and animal health Oncology and vaccine franchises anchor clinical presence ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results